Study Evaluating How Acetaldehyde from Alcohol May Influence Oral Cancer Development in Adults Aged 18 to 45

What this Trial Is About

Researchers are studying the role of acetaldehyde, a substance produced when the body processes alcohol, in the development of oral cancer. This minimal risk intervention study involves healthy volunteers and individuals with Fanconi anemia, aiming to understand how acetaldehyde exposure in the mouth may contribute to cancer risk. The study is sponsored by the Masonic Cancer Center at the University of Minnesota and includes participants aged 18 to 45 years. Participants are divided into two groups. One group consumes a single dose of alcohol designed to reach a blood alcohol concentration of 0.03%, followed by saliva and breathalyzer tests at various times. The other group, who do not drink alcohol, provide saliva and oral cell samples collected through mouthwash and cheek brush methods. Two optional blood samples may also be collected and stored for future research. Samples like saliva, oral cells, and urine are collected at multiple time points to analyze acetaldehyde levels and confirm non-smoking status. During the study, participants provide biological samples before and after alcohol intake or at similar times if they do not consume alcohol. Saliva is tested at multiple intervals up to six hours after alcohol consumption to measure acetaldehyde exposure. Urine is analyzed to confirm smoking status both before and after the study procedures. Participants undergo breathalyzer tests to monitor alcohol levels. The study monitors these measures to better understand acetaldehydes impact on oral health, with the entire participation lasting for the duration of the sample collection period on the study day.

Role of Acetaldehyde in the Development of Oral Cancer